Can we optimize antibiotic dosing for children with sepsis?

NCT ID NCT03133910

Completed Knowledge-focused Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks at how the antibiotic ceftazidime behaves in children with sepsis who are in the intensive care unit (ICU). Sepsis changes the body rapidly, which can affect drug levels. The goal is to see if current dosing keeps enough antibiotic in the blood to fight bacteria effectively. Researchers will measure drug concentrations in about 13 children aged 2 months to 18 years who are already receiving ceftazidime.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftazidime
What this could lead to: If successful, this could lead to better antibiotic dosing strategies for critically ill children with sepsis, potentially improving treatment outcomes.
What could go wrong: This is a small, early-phase study focused on drug levels, not clinical outcomes. Results may not apply to all ICU patients, and the drug's effectiveness could still vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS

Contacts and locations

Locations

Ann & Robert H Lurie Childjren's Hospital of Chicago

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.